Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
The Cancer Journal From Scientific American|February 24, 2000
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinomaR I Fisher, S A Rosenberg, G FyfeThe Cancer Journal From Scientific American|February 11, 1998
High-dose aldesleukin in renal cell carcinoma: long-term survival updateR I Fisher, S A Rosenberg, M Sznol, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1995
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapyG Fyfe, R I Fisher, S A Rosenberg, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1987
Subpopulations of B lymphocytes in germinal centersG Fyfe, J A Cebra-Thomas, E Mustain, et al.Stem Cells (Dayton, Ohio)|September 30, 2000
Recombinant human thrombopoietin clinical developmentD V Jones, M Ashby, S Vadhan-Raj, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcomaF A Momin, M Zalupski, L K Heilbrun, et al.The Journal of Infectious Diseases|November 7, 1998
Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study GroupA Carr, S Emery, A Lloyd, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety dataK Margolin, M S Gordon, E Holmgren, et al.Investigational New Drugs|May 1, 1993
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinomaR M Bukowski, J Young, G Goodman, et al.Cancer|November 1, 1993
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumorsJ E Janik, M Sznol, W J Urba, et al.Pageof 2